bioaccess.™: CRO. REGULATORY. COMMERCIALIZATION

View Original

Human Med Chooses bioaccess to Launch the innovative body jet in Colombia —The best Liposuction and Lipotransfer Equipment in the World

[FEBRUARY 25, 2020, ORLANDO, FL] Human Med AG, a progressive Germ manufacturer of progressive medical technology devices, has chosen bioaccess™ to obtain regulatory registration and market clearance for its body-jet® line of products at INVIMA in Colombia.

Human Med AG is the world’s leading manufacturer of water-jet assisted liposuction devices, consumables, and accessories for autologous adipose cell grafting; the company has more than 20 years of experience in product development and manufacturing in the field of surgical water-jet dissection (hydro dissection) and has its own R&D department.

The well-proven and reliable body-jet® uses the gentle power of water for body contouring. Using the body-jet®, liposuction is performed in a safe, effective and easy way.

Unlike conventional liposuction methods, during the water-jet assisted liposuction (WAL) and the water-jet assisted fat transfer, the fat is gently detached from the tissue structure by means of a flat, fan-shaped water-jet and may be aspirated at the same time. The surrounding connective tissue, nerves and blood vessels remain much less traumatized. WAL allows for excellent aesthetic results, the risks remain minimal and the healing process is fast.

About Human Med AG

Human Med AG is a progressive German manufacturer of medical technology devices and is a leader in the field of water-jet assisted liposuction and autologous fat transplantation (WAL). Human Med AG is considered the world’s leading manufacturer of water-jet assisted liposuction devices, consumables, and accessories for autologous adipose cell grafting. More information at www.humanmed.com.

About bioaccess™

bioaccess™ —a Florida-based clinical research organization (CRO) with the mission to help innovative life science companies conduct clinical research and commercialize their innovations in Colombia— will design the Libella study and will provide support services (e.g., IRB submission, logistical support, project management, statistical analysis, and study monitoring; among others). More information at www.bioaccessla.com.

###

Media Contact:

Julio G. Martinez-Clark

CEO, bioaccess™

jmclark@bioaccessla.com

+1 (954) 903-7210